Use of SGLT2i versus DPP4i as an Add-On Therapy and the Risk of PAD-Related Surgical Events (Amputation, Stent Placement, or Vascular Surgery): A Cohort Study in Veterans with Diabetes

• DOI: 10.2337/figshare.27629499.v1
• Publication Date: 2024-12-02T20:16:55Z
• Authors: Katherine E. Griffin; Kathryn Snyder; Amir H. Javid; Amber Hackstadt; Robert Greevy; Carlos G. Grijalva; Christianne L. Ro...
• Keywords: 03 medical and health sciences; 0302 clinical medicine

<p dir="ltr">Objective: To compare the risk of composite peripheral artery disease (PAD) surgical outcome, including revascularization and amputation procedures, between new users sodium-glucose cotransporter-2 inhibitors (SGLT2i) dipeptidyl peptidase-4 (DPP4i). </p><p dir="ltr">Research Design Methods: Retrospective cohort U.S. Veterans > 18 years old with diabetes who received care from Health Administration 10/01/2000 to 12/31/2021. Data were linked Medicare, Medicaid, National Death Index. New use SGLT2i or DPP4i medications as addition metformin, sulfonylurea, insulin treatment alone in combination was evaluated for an association PAD procedure amputation. A Cox proportional hazards model time-to-PAD event analysis compared a propensity-score weighted cohort, competing death allowing events occur up 90 days 360 after stopping SGLT2i.</p><p dir="ltr">Results: The included 76,072 vs 75,833 episodes. median age 69 old, HbA1c 8.4 [7.5, 9.4], duration 10.1 [6.6, 14.6] years. There 874 780 among users, respectively, rate 11.2 (10.5-11.9) 10.0 (9.4-10.6) per 1000 person-years (aHR 1.18 [1.08, 1.29]). When allowed ended, aHR 1.16 [1.06, 1.26]). dir="ltr">Conclusion: add-on therapy associated increased cause specific hazard surgeries DPP4i.</p>